EntryPoint Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $505K | Sell |
1,550
-814
| -34% | -$265K | 0.25% | 95 |
|
|
2025
Q1 | $638K | Sell |
2,364
-178
| -7% | -$48.1K | 0.29% | 38 |
|
|
2024
Q4 | $598K | Buy |
2,542
+948
| +59% | +$223K | 0.25% | 57 |
|
|
2024
Q3 | $438K | Buy |
+1,594
| New | +$438K | 0.25% | 93 |
|
|
2024
Q2 | – | Sell |
-1,724
| Closed | -$258K | – | 857 |
|
|
2024
Q1 | $258K | Buy |
1,724
+711
| +70% | +$106K | 0.23% | 49 |
|
|
2023
Q4 | $194K | Buy |
+1,013
| New | +$194K | 0.19% | 104 |
|